24/7 Market News- FDA Lifts Partial Clinical Hold on Zentalis Pharmaceuticals Azenosertib Studies

September 16, 2024

DENVER, Colo., Sep 16, 2024 (247marketnews.com)- Zentalis Pharmaceuticals (Nasdaq: ZNTL) stated that the Company will be work with its clinical trial investigators to resume study activities across the azenosertib development program as quickly as possible. The move follows the U.S. Food and Drug Administration (FDA) clearing the Company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan.

Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis Pharmaceuticals, commented, “We are grateful to the FDA for their collaboration and review of our complete response package, which included a comprehensive safety assessment of the azenosertib program.

“We are extremely pleased with the successful resolution of the partial clinical hold. Our confidence in the therapeutic index of azenosertib has been unwavering, and we continue to believe in the potential for this treatment to address unmet medical needs faced by people living with gynecologic malignancies.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (ZNTL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.